NewsEPILEPTIC DISORDERS : INTERNATIONAL EPILEPSY JOURNAL WITH VIDEOTAPEThursday, April 16, 2026 · April 16, 2026
A temporary spike: Investigating Lennox-Gastaut syndrome incidence in the US following FDA approval of cannabidiol.
WHY IT MATTERS
Recent peer-reviewed research on Lennox-Gastaut syndrome that may be relevant for patients and caregivers.
In June 2018, the US Food and Drug Administration (FDA) approved pharmaceutical grade cannabidiol (CBD; Epidiolex®) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS). We sought to examine whether the FDA approval of CBD was associated with changes in LGS diagnostic pra...
Related conditions
Related news
Int J Circumpolar Health · -222 days ago
A population-based legacy study of myasthenia gravis in Iceland: insights from a small Arctic nation
Published in Int J Circumpolar Health. Hjaltason H et al.…
Ther Adv Rare Dis · -192 days ago
Could an outcome-based agreement be operationalized using real-world data from the Canadian Neuromuscular Disease Registry? Perspectives from an expert-led assessment in spinal muscular atrophy
Published in Ther Adv Rare Dis. Mitha A et al.…
Health Inf Sci Syst · -192 days ago
PhenoRareAI: Phenotype-based intelligent diagnosis for rare neuromuscular disorders of glycogen storage disease and spinal muscular atrophy
Published in Health Inf Sci Syst. Zhai W et al.…
J Allergy Clin Immunol Glob · -39 days ago
Emerging trends and research hot spots in inborn error of immunity: A bibliometric perspective
Published in J Allergy Clin Immunol Glob. Alblooshi H et al.…